RxTrials Institute Drug Pipeline Alert

Orexo has completed a pharmocological profile study of Sublinox for treatment of temporary sleeping disturbances.

Sublinox (OX22), which contains zolpidem, is based on Orexo’s sublingual technology involving a tablet placed under the tongue for fast, effective absorption of the active substance across the oral mucosa.

The study showed that Sublinox acts 30 percent faster than sanofi-aventis’ Ambien as a sleep aid, according to Orexo.

The study will be part of the registration application Orexo plans to submit to the FDA later this year.